Detalhe da pesquisa
1.
Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse.
Cytokine
; 175: 156485, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38159470
2.
Plasma C18:0-ceramide is a novel potential biomarker for disease severity in myasthenia gravis.
J Neurochem
; 165(6): 907-919, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37158660
3.
Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.
Neurol Sci
; 44(11): 3877-3884, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37402938
4.
The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis.
Ann Clin Transl Neurol
; 10(1): 98-110, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36453129
5.
Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
J Neurol
; 271(1): 584-588, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37804335
6.
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
J Neurol
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38602546